Molecular markers are an increasingly important part of gynecological cancer diagnosis. In this test-specific episode of the "Answers From the Lab" podcast, Sounak Gupta, M.B.B.S., Ph.D., explains why Mayo Clinic Laboratories' gynecological NGS panels are a cost-effective way to inform prognosis and individualized treatment.

"These panels fill a hole in our test menu with regards to certain disease states where we may want to test for just a handful of genes," Dr. Sounak says. "Our large cancer panel, which is over 500 genes, would give us this information. But we wanted to make a very focused, cost-effective test for patients with gynecologic malignancies."

Mayo Clinic Laboratories consulted gynecologic surgeons, medical oncologists, and pathologists to determine which genes to include in the ovarian and gynecological panels.

"Whether it's ovarian cancer or endometrial cancer, we've paid particular attention to biomarkers that can lead to improved patient management," Dr. Sounak says. "The focus ultimately is to have the best test for each patient."

Listen to learn more about Mayo Clinic Laboratories' gynecological NGS panels.

Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.

Testing

MCGYN | MayoComplete Gynecological Cancer Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 49 genes.

MCECP | MayoComplete Endometrial Carcinoma Panel, Next-Generation Sequencing, Tumor

• Provides diagnostic, prognostic, and therapeutic insights based on assessment of 19 genes.

MCOCP | MayoComplete Ovarian, Fallopian Tube, and Peritoneal Cancer Panel, Next-Generation Sequencing, Tumor

• Provides therapeutic insights based on assessment of 14 genes.

The latest

Unique Test Screens for Recently Identified Peripheral Neuropathy: Matthew Schultz, Ph.D., and Amy White, M.S., CGC

September 24, 2024

Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related peripheral neuropathy is fairly common.

Panel Detects Demyelinating Neuropathy Biomarkers: John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S.

September 17, 2024

John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.

Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D.

September 10, 2024

Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.

View MoreView Less